Pratt, Guy, Yap, Christina, Oldreive, Ceri, Slade, Daniel, Bishop, Rebecca, Griffiths, Mike, Dyer, Martin JS, Fegan, Chris, Oscier, David, Pettitt, Andrew 
ORCID: 0000-0002-0907-8950 et al (show 9 more authors)
(2018)
A multi-centre phase I trial of the PARP inhibitor olaparib in patients with relapsed chronic lymphocytic leukaemia, T-prolymphocytic leukaemia or mantle cell lymphoma.
BRITISH JOURNAL OF HAEMATOLOGY, 182 (3).
pp. 429-433.
ISSN 0007-1048, 1365-2141
![[thumbnail of PICLLe BJH letter-April 2017.docx]](https://livrepository.liverpool.ac.uk/style/images/fileicons/text.png) |
Text
PICLLe BJH letter-April 2017.docx - Author Accepted Manuscript Download (62kB) |
|
Text
Letter_Table_1_25_01_2017.pdf - Author Accepted Manuscript Download (12kB) |
|
Text
Letter_Table_2_25_01_2017.pdf - Author Accepted Manuscript Download (24kB) |
Official URL: https://doi.org/10.1111/bjh.14793
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | chronic lymphocytic leukaemia, mantle cell lymphoma, DNA damage, olaparib |
| Depositing User: | Symplectic Admin |
| Date Deposited: | 17 Sep 2018 10:45 |
| Last Modified: | 07 Dec 2024 19:34 |
| DOI: | 10.1111/bjh.14793 |
| Related URLs: | |
| URI: | https://livrepository.liverpool.ac.uk/id/eprint/3026120 |
Altmetric
Altmetric
